AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
With training and planning, self-injecting your rheumatoid arthritis medication may be easier than you think.
New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.